中华眼视光学与视觉科学杂志
中華眼視光學與視覺科學雜誌
중화안시광학여시각과학잡지
CHINESE JOURNAL OF OPTOMETRY OPHTHALMOLOGY AND VISUAL SCIENCE
2014年
8期
500-503
,共4页
龙潭%马挺%梁厚成%田华
龍潭%馬挺%樑厚成%田華
룡담%마정%량후성%전화
可植入性眼内接触镜%Lenstar%近视,退行性
可植入性眼內接觸鏡%Lenstar%近視,退行性
가식입성안내접촉경%Lenstar%근시,퇴행성
Implantable intraocular contact lens%Lenstar%Myopia,degenerative
目的 评估Lenstar LS900在可植入性眼内接触镜(ICL)植入术中的应用.方法 回顾性系列病例分析.分析2012年1月-2013年6月在西安市眼科医院接受ICL植入的高度近视患者的临床资料,对术前及术后视力(logMAR)、眼压、角膜内皮细胞计数进行比较,并于术后行UBM检查分析术后ICL拱高、距巩膜突500 μm房角开放距离(AOD 500),观察虹膜前表面形态.对数据采用配对t检验、重复测量的方差分析、Pearson相关分析进行检验.结果 共27例患者(54眼)纳入该项研究.术后所有患者裸眼视力(logMAR) (0.06±0.05)均较术前(1.22±0.33)有明显的提高(t=25.306,P＜0.01),与术前最佳矫正视力(logMAR) (0.06±0.05)差异无统计学意义(t=-0.640,P＞0.05).术后等效球镜度为(-0.21±0.10)D,较术前的(-9.34±1.97)D显著降低(t=34.304,P＜0.01).术后眼压为(14.93±2.12)mmHg,与术前的(13.82±1.83)mmHg比较差异无统计学意义(t=1.851,P＞0.05).术后3个月时内皮细胞丢失率为(2.69±2.16)％.术后3个月72％患眼的ICL拱高在理想范围内.所有患者在随访期间均未出现白内障.结论 Lenstar LS900在ICL植入术中的应用是安全、有效的,术后可获得精确的预期屈光度,且术后绝大部分患者ICL拱高均在理想范围内.
目的 評估Lenstar LS900在可植入性眼內接觸鏡(ICL)植入術中的應用.方法 迴顧性繫列病例分析.分析2012年1月-2013年6月在西安市眼科醫院接受ICL植入的高度近視患者的臨床資料,對術前及術後視力(logMAR)、眼壓、角膜內皮細胞計數進行比較,併于術後行UBM檢查分析術後ICL拱高、距鞏膜突500 μm房角開放距離(AOD 500),觀察虹膜前錶麵形態.對數據採用配對t檢驗、重複測量的方差分析、Pearson相關分析進行檢驗.結果 共27例患者(54眼)納入該項研究.術後所有患者裸眼視力(logMAR) (0.06±0.05)均較術前(1.22±0.33)有明顯的提高(t=25.306,P＜0.01),與術前最佳矯正視力(logMAR) (0.06±0.05)差異無統計學意義(t=-0.640,P＞0.05).術後等效毬鏡度為(-0.21±0.10)D,較術前的(-9.34±1.97)D顯著降低(t=34.304,P＜0.01).術後眼壓為(14.93±2.12)mmHg,與術前的(13.82±1.83)mmHg比較差異無統計學意義(t=1.851,P＞0.05).術後3箇月時內皮細胞丟失率為(2.69±2.16)％.術後3箇月72％患眼的ICL拱高在理想範圍內.所有患者在隨訪期間均未齣現白內障.結論 Lenstar LS900在ICL植入術中的應用是安全、有效的,術後可穫得精確的預期屈光度,且術後絕大部分患者ICL拱高均在理想範圍內.
목적 평고Lenstar LS900재가식입성안내접촉경(ICL)식입술중적응용.방법 회고성계렬병례분석.분석2012년1월-2013년6월재서안시안과의원접수ICL식입적고도근시환자적림상자료,대술전급술후시력(logMAR)、안압、각막내피세포계수진행비교,병우술후행UBM검사분석술후ICL공고、거공막돌500 μm방각개방거리(AOD 500),관찰홍막전표면형태.대수거채용배대t검험、중복측량적방차분석、Pearson상관분석진행검험.결과 공27례환자(54안)납입해항연구.술후소유환자라안시력(logMAR) (0.06±0.05)균교술전(1.22±0.33)유명현적제고(t=25.306,P＜0.01),여술전최가교정시력(logMAR) (0.06±0.05)차이무통계학의의(t=-0.640,P＞0.05).술후등효구경도위(-0.21±0.10)D,교술전적(-9.34±1.97)D현저강저(t=34.304,P＜0.01).술후안압위(14.93±2.12)mmHg,여술전적(13.82±1.83)mmHg비교차이무통계학의의(t=1.851,P＞0.05).술후3개월시내피세포주실솔위(2.69±2.16)％.술후3개월72％환안적ICL공고재이상범위내.소유환자재수방기간균미출현백내장.결론 Lenstar LS900재ICL식입술중적응용시안전、유효적,술후가획득정학적예기굴광도,차술후절대부분환자ICL공고균재이상범위내.
Objective To evaluate the use of Lenstar LS900 in the implantation of an intraocular contact lens (Visian Implantable Collamer Lens,ICL).Methods The clinical data of patients with hypermyopia who underwent ICL implantation from January 2012 to June 2013 were retrospectively analyzed.Comparisons between preoperative and postoperative visual acuity (logMAR),intraocular pressure,and comeal endothelial cell were measured.Postoperative ICL vault,angle-opening distance 500 μm from the scleral spur (AOD 500),and the shape of the anterior surface of the iris were evaluated.The measurement data were analyzed with a paired t test,and the correlation between preoperative spherical equivalent and predicted error (PE) was done with Pearson correlation analysis.Results Twenty-seven patients (54 eyes) were included.Postoperative uncorrected visual acuity (UCVA) (0.06±0.05) improved significantly compared with preoperative UCVA (1.22±0.33)(t=25.306,P＜0.01),and there was no statistically significant difference with preoperative best corrected visual acuity (BCVA) (0.06±0.05) (t =-0.640,P＞0.05).Postoperative spherical equivalent (SE) error (-0.21±0.1 D) decreased significantly compared with preoperative SE error (-9.34±1.97 D)(t=34.304,P＜0.01).There was no significant difference between preoperative and postoperative intraocular pressure (13.82±1.83 mmHg and 14.93±2.12 mmHg,respectively) (t=1.851,P＞0.05).The endothelial cell loss rate at 3 months postoperatively was 2.69％±2.16％.ICL vault for 72％ of the eyes was in the ideal range at 3 months postoperatively.No cataracts formed in any of the patients during the follow-up period.Conclusion The use of Lenstar LS900 in ICL implantation is safe and effective.Postoperative refractive error is accurate,and the ICL vault is in an ideal range in most patients.
